MaxCyte, Inc. (MXCT) stock
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3065% below fair value
$1.17−0.01 (-0.85%)
Close on Nov 17, 2026Market cap $120.75MP/E –Yield –
MaxCyte shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
MaxCyte's shares outstanding was 107M at Jun 30, 2026. For fiscal 2025 it was 106M, up 1.5% from the year before. The highest annual figure on record is 106M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 106M | +1.5% |
| FY2024 | Dec 31, 2024 | 105M | +1.5% |
| FY2023 | Dec 31, 2023 | 103M | +1.5% |
| FY2022 | Dec 31, 2022 | 102M | +12.2% |
| FY2021 | Dec 31, 2021 | 91M | +30.5% |
| FY2020 | Dec 31, 2020 | 69M | +23.2% |
| FY2019 | Dec 31, 2019 | 56M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 107M | +0.4% |
| Q1 FY2026 | Mar 31, 2026 | 107M | +0.9% |
| Q4 FY2025 | Dec 31, 2025 | 107M | +1.1% |
| Q3 FY2025 | Sep 30, 2025 | 107M | +1.4% |
| Q2 FY2025 | Jun 30, 2025 | 106M | +1.7% |
| Q1 FY2025 | Mar 31, 2025 | 106M | +1.8% |
| Q4 FY2024 | Dec 31, 2024 | 106M | +1.8% |
| Q3 FY2024 | Sep 30, 2024 | 105M | +1.6% |
| Q2 FY2024 | Jun 30, 2024 | 105M | +1.5% |
| Q1 FY2024 | Mar 31, 2024 | 104M | +1.2% |
| Q4 FY2023 | Dec 31, 2023 | 104M | +1.5% |
| Q3 FY2023 | Sep 30, 2023 | 103M | +1.6% |
| Q2 FY2023 | Jun 30, 2023 | 103M | +1.6% |
| Q1 FY2023 | Mar 31, 2023 | 103M | +1.5% |
| Q4 FY2022 | Dec 31, 2022 | 102M | +1.2% |
| Q3 FY2022 | Sep 30, 2022 | 102M | +20.2% |
| Q2 FY2022 | Jun 30, 2022 | 101M | +19.7% |
| Q1 FY2022 | Mar 31, 2022 | 101M | +25.1% |
| Q4 FY2021 | Dec 31, 2021 | 101M | +30.4% |
| Q3 FY2021 | Sep 30, 2021 | 85M | +9.9% |
| Q2 FY2021 | Jun 30, 2021 | 85M | +28.7% |
| Q1 FY2021 | Mar 31, 2021 | 81M | – |
| Q4 FY2020 | Dec 31, 2020 | 77M | – |
| Q3 FY2020 | Sep 30, 2020 | 77M | – |
| Q2 FY2020 | Jun 30, 2020 | 66M | – |
See a number that looks wrong?